Ocuphire Pharma Investor Presentation Deck
U.S Diabetic Retinopathy Market
Majority of the DR patients are NPDR Severity →Target Population for APX3330
Types of DR
Target Patient
Population
Ocuphire
34 Million Diabetics in US
10M Diabetic Retinopathy (DR)
Non-Proliferative
DR
US Market
Opportunity
Proliferative
DR
8M
NPDR Patients
~$6B+
78%
NPDR
Real-World Chart Review of DR Patients in US
% of Patients
American Diabetes Association; International Diabetes Federation; Healthline; *Ocuphire internal analysis and assumptions; Spherix Global Insights
Patient survey adapted from Lions International Foundation and International Diabetes Foundation-Europe; Meltzer 2000
Estimates are provided by the National Eye Institute, FactSheet, Global Data, and Research and Markets. Estimated values are rounded.
Estimated prevalence in the U.S.; DME- Diabetic Macular Edema; Age-related Macular Degeneration; Geographic Atrophy; Retinal Vein Occlusion
22%
24%
27%
27%
Proliferative diabetic retinopathy
(PDR)
Severe non-proliferative diabetic
retinopathy
(NPDR)
Moderate non-proliferative
diabetic retinopathy
(NPDR)
Mild non-proliferative diabetic
retinopathy
(NPDR)
8View entire presentation